

## DAFTAR PUSTAKA

- Agoes, Goeswin. Pengembangan Sediaan Farmasi. Edisi Revisi dan Perluasan. Penerbit ITB : Bandung. 2008
- Ansel, H. C. Pengantar Bentuk Sediaan Farmasi, Edisi Keempat, terjemahan Ibrahim dan Farida, Universitas Indonesia Press, Jakarta. 1989.
- Bergström, C. A. S., Box, K., Holm, R., Matthews, W., McAllister, M., Müllertz, A., Rades, T., Schäfer, K. J., & Teleki, A. (2019). Biorelevant intrinsic dissolution profiling in early drug development: Fundamental, methodological, and industrial aspects. In *European Journal of PHarmaceutics and BiopHarmaceutics* (Vol. 139, pp. 101–114). Elsevier B.V. <https://doi.org/10.1016/j.ejpb.2019.03.011>
- Bruni, G., Maietta, M., Maggi, L., Mustarelli, P., Ferrara, C., Berbenni, V., Milanese, C., Girella, A., & Marini, A. (2013). Preparation and pHysicochemical characterization of acyclovir cocrystals with improved dissolution properties. *Journal of PHarmaceutical Sciences*, 102(11), 4079–4086. <https://doi.org/10.1002/jps.23721>
- Budiarto, S., & Binarjo, A. (2012). *Enhancement Of Piroxicam Intrinsic Dissolution Rate With Solid Dispersion System Using Beta Cyclodextrin*.
- Cailletaud, J., de Bleye, C., Dumont, E., Sacré, P. Y., Gut, Y., Leblanc, N., Letellier, P., Ginot, Y. M., Hubert, P., & Ziemons, E. (2020). Detection of low dose of piroxicam polymorphH in pHarmaceutical tablets by surface-enhanced Raman chemical imaging (SER-CI) and multivariate analysis. *International Journal of PHarmaceutics*, 574. <https://doi.org/10.1016/j.ijpHarm.2019.118913>
- Chatterjee, A., Gupta, M., & Srivastava, B. (2017). *Spherical* crystallization: A technique use to reform solubility and flow property of active pHarmaceutical ingredients. *International Journal of PHarmaceutical Investigation*, 7(1), 4. [https://doi.org/10.4103/jpHi.jpHi\\_36\\_16](https://doi.org/10.4103/jpHi.jpHi_36_16)
- Chen, H., Guo, Y., Wang, C., Dun, J., & Sun, C. C. (2019). *Spherical* Cocrystallization - An Enabling Technology for the Development of High Dose Direct Compression Tablets of Poorly Soluble Drugs. *Crystal Growth and Design*, 19(4), 2503–2510. <https://doi.org/10.1021/acs.cgd.9b00219>
- Chen, H., Wang, C., Liu, S., & Sun, C. C. (2020). Development of piroxicam mini-tablets enabled by *spherical* cocrystallization. *International Journal of PHarmaceutics*, 590. <https://doi.org/10.1016/j.ijpHarm.2020.119953>
- Chen, H., Xu, H., Wang, C., Kang, H., Haynes, C. L., Mahanthappa, M. K., & Sun, C. C. (2020). Novel Quasi-Emulsion Solvent Diffusion-Based *Spherical*

- Cocrystallization Strategy for Simultaneously Improving the Manufacturability and Dissolution of Indomethacin. *Crystal Growth and Design*, 20(10), 6752–6762. <https://doi.org/10.1021/acs.cgd.0c00876>
- Depkes RI. (2020). Farmakope Indonesia Edisi Vi 2020 Kementerian Kesehatan Republik Indonesia.
- Fadhila, M., Umar, S., & Zaini, E. (2020). Pembentukan Kokristal Asam Usnat – N-Methyl-DGlucamine dengan Metode Penguapan Pelarut dan Pengaruhnya terhadap Penurunan Interleukin-8 pada Tikus Inflamasi. *Jurnal Sains Farmasi & Klinis*, 7(1), 23. <https://doi.org/10.25077/jsfk.7.1.23-30.2020>
- Florey, K. (1986). *Analytical Profiles of Drug Substances. Volume 15*.
- Gallo, M., Serpella, L., Leone, F., Manna, L., Banchemo, M., Ronchetti, S., & Onida, B. (2021). Piroxicam loading onto mesoporous silicas by supercritical CO<sub>2</sub> impregnation. *Molecules*, 26(9). <https://doi.org/10.3390/molecules26092500>
- Guo, M., Sun, X., Chen, J., & Cai, T. (2021). PHarmaceutical cocrystals: A review of preparations, pHysicochemical properties and applications. In *Acta PHarmaceutica Sinica B* (Vol. 11, Issue 8, pp. 2537–2564). Chinese Academy of Medical Sciences. <https://doi.org/10.1016/j.apsb.2021.03.030>
- Indra, I., Janah, F. M., & Aryani, R. (2019). Enhancing the Solubility of Ketoconazole via PHarmaceutical Cocrystal. *Journal of PHysics: Conference Series*, 1179(1). <https://doi.org/10.1088/1742-6596/1179/1/012134>
- Issa, M. G., & Ferraz, H. G. (2011a). Intrinsic dissolution as a tool for evaluating drug solubility in accordance with the biopHarmaceutics classification system. *Dissolution Technologies*, 18(3), 6–13. <https://doi.org/10.14227/DT180311P6>
- Issa, M. G., & Ferraz, H. G. (2011b). Intrinsic dissolution as a tool for evaluating drug solubility in accordance with the biopHarmaceutics classification system. *Dissolution Technologies*, 18(3), 6–13. <https://doi.org/10.14227/DT180311P6>
- Karagianni, A., Malamataris, M., & Kachrimanis, K. (2018). PHarmaceutical cocrystals: New solid pHase modification approaches for the formulation of APIs. In *PHarmaceutics* (Vol. 10, Issue 1). MDPI AG. <https://doi.org/10.3390/pHarmaceutics10010018>
- Lachman, Leon, Herbert A. Lieberman, Joseph L. Kanig. The Theory and Practice of Industrial PHarmacy 2nd edition. Lea & Febiger: PHiladelphHia, 1970: h.31, 118.
- Liu, X., Michalchuk, A. A. L., Pulham, C. R., & Boldyreva, E. v. (2019). An acetonitrile-solvated cocrystal of piroksikam and succinic acid with co-existing zwitterionic and non-ionized piroksikam molecules. *Acta CrystallographHica Section C: Structural Chemistry*, 75(1), 29–37. <https://doi.org/10.1107/S2053229618016911>

- Lu, E., Rodriguez-Hornedo, N., Suryanarayanan, R., 2008. A rapid thermal method for cocrystal screening. *CrystEngComm* 10, 665–668.
- Maghsoodi, M., & Sadeghpour, F. (2010). Preparation and evaluation of solid dispersions of piroxicam and Eudragit S100 by *spherical* crystallization technique. *Drug Development and Industrial PHarmacy*, 36(8), 917–925. <https://doi.org/10.3109/03639040903585127>
- Maghsoodi M. 2015. Role of solvents in improvements of dissolution rate of drugs: Crystal habit and crystal agglomeration. *Adv PHarm Bull.* 5. 13-8.
- Modani, S., Gunnam, A., Yadav, B., Nangia, A. K., Nangia, A. K., & Shastri, N. R. (2020). Generation and Evaluation of PHarmacologically Relevant Drug-Drug Cocrystal for Gout Therapy. *Crystal Growth and Design*, 20(6), 3577–3583. <https://doi.org/10.1021/acs.cgd.0c00106>
- Mohammad, M.A., Alhalaweh, A., Velaga, S.P., 2011. Hansen solubility parameter as a tool to predict cocrystal formation. *Int. J. PHarm.* 407, 63–71.
- Mostafa, G. A. E., Al-Dosseri, A. S., & Al-Badr, A. A. (2020). Piroxicam. *Profiles of Drug Substances, Excipients and Related Methodology*, 45, 199–474. <https://doi.org/10.1016/bs.podrm.2019.10.007>
- Mostafa Nowee, S., Abbas, A., & Romagnoli, J. A. (2008). Antisolvent crystallization: Model identification, experimental validation and dynamic simulation. *Chemical Engineering Science*, 63(22), 5457–5467. <https://doi.org/10.1016/j.ces.2008.08.003>
- Nangia, A. K., & Desiraju, G. R. (2019). Kristall-Engineering: ein Blick in die Zukunft. *Angewandte Chemie*, 131(13), 4142–4150. <https://doi.org/10.1002/ange.201811313>
- Ohannesian, Lena., & Streeter, A. J. (2002). *Handbook of pHarmaceutical analysis*. Marcel Dekker.
- Ostergaard, I., & Qu, H. (2021). Solubility and Crystallization of Piroxicam from Different Solvents in Evaporative and Cooling Crystallization. *Crystals*, 11(12). <https://doi.org/10.3390/cryst11121552>
- Panzade, P., & Shendarkar, G. (2019). Design and preparation of zaltoprofen-nicotinamide pHarmaceutical cocrystals via liquid assisted grinding method. *Indian Journal of PHarmaceutical Education and Research*, 53(4), S563–S570. <https://doi.org/10.5530/ijper.53.4s.151>
- Panzade, P., Shendarkar, G., Shaikh, S., & Rathi, P. B. (2017). Pharmaceutical Cocrystal of Piroksikam: Design, formulation, and evaluation. *Advanced PHarmaceutical Bulletin*, 7(3), 399–408. <https://doi.org/10.15171/apb.2017.048>

- Qiao, N., Li, M., Schlindwein, W., Malek, N., Davies, A., & Trappitt, G. (2011). PHarmaceutical cocrystals: An overview. In *International Journal of PHarmaceutics* (Vol. 419, Issues 1–2, pp. 1–11). Elsevier B.V. <https://doi.org/10.1016/j.ijpHarm.2011.07.037>
- Schultheiss, N., & Newman, A. (2009). PHarmaceutical cocrystals and their pHysicochemical properties. In *Crystal Growth and Design* (Vol. 9, Issue 6, pp. 2950–2967). <https://doi.org/10.1021/cg900129f>
- Shohin, I. E., Kulinich, J. I., Ramenskaya, G. V., Abrahamsson, B., Kopp, S., Langguth, P., Polli, J. E., Shah, V. P., Groot, D. W., Barends, D. M., & Dressman, J. B. (2014). Biowaiver monographHs for immediate release solid oral dosage forms: Piroxicam. *Journal of PHarmaceutical Sciences*, 103(2), 367–377. <https://doi.org/10.1002/jps.23799>
- Singh, G., & Pandey, P. M. (2020). Neck growth kinetics during ultrasonic-assisted sintering of copper powder. *Proceedings of the Institution of Mechanical Engineers, Part C: Journal of Mechanical Engineering Science*, 234(11), 2178–2188. <https://doi.org/10.1177/0954406220904108>
- Sudarsanam, P., Sireesha, V., Prasad, P. V., & Saritha, K. (2016). Formulation And Evaluation Of Piroxicam Delayed Release Tablets. *International Journal Of PHarmaceutics & Drug Analysis*, 4, 318–328. <http://ijpda.com>;
- Sulistyowaty, M. I., Setyawan, D., Sari, R., Paramanandana, A., Maharani, N. A., & Simorangkir, T. P. (2022). Preparation and PHysicochemical Characterizations of p-Methoxycinnamic acid – Succinic Acid Cocrystal by Solvent Evaporation Technique. *Open Access Macedonian Journal of Medical Sciences*, 10(A), 1444–1449. <https://doi.org/10.3889/oamjms.2022.10193>
- Sweetman, C. Sean. *Martindale the Complete Drug Reference* 36th edition. Pharmaceutical Press: London, 2009.
- Thakuria, Ranjit, Amit Deloria, William Jonesa, Maya P. Lipertb, Lilly Royb, Naír Rodríguez-Hornedo. PHarmaceutical cocrystals and poorly soluble drugs: Elsevier: US. 2013
- Thenge, R. R., Chandak, M. P., & Adhao, V. S. (2020). *Spherical Crystallization: A Tool to Improve the PHysicochemical Properties of APIs*. *Asian Journal of PHarmaceutical Research and Development*, 8(3), 104–110. <https://doi.org/10.22270/ajprd.v8i3.727>
- Yao, C., Guzei, I. A., Jin, Y., Ruan, S., Sun, G., Gui, Y., Wang, L., & Yu, L. (2020). PolymorpHism of Piroxicam: New PolymorpHs by Melt Crystallization and Crystal Structure Prediction. *Crystal Growth and Design*, 20(12), 7874–7881. <https://doi.org/10.1021/acs.cgd.0c01165>

Yu, L. X.; Carlin, A. S.; Amidon, G. L.; Hussain A. S. Feasibility studies of utilizing disk intrinsic dissolution rate to classify drugs. *Int. J. PHarm.* 2004, 270 (1–2), 221–227.

Yu, L. X.; Carlin A. S.; Hussain, A. S. Feasibility Studies of Intrinsic Dissolution Rate as an Alternative Method to Determine BCS Solubility Membership. Presented at the American Association of PHarmaceutical Sciences annual meeting, 2000.